A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Status:
Completed
Trial end date:
1993-03-01
Target enrollment:
Participant gender:
Summary
To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen.
To determine the effect of antiretroviral therapy on vaccine responsiveness.
Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been
hypothesized that HIV-specific immune responses are responsible for the period of relative
quiescence of viral replication. Recent studies suggest that these immune functions can be
augmented by vaccination with HIV-derived antigens.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)